CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Study Summary

The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).

Conditions

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Interventions / Drugs

Cardiac MRI

View on ClinicalTrials.gov ↗

Sponsor

IONS

Ionis Pharmaceuticals

Antisense Therapeutics

B68/100

Study Details

Enrollment150 participants

Primary Completion—

Lead SponsorIonis Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:17:53.139366+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.